Stockscreener 앱 받기
26.90
0.44%
-0.12
Maplight Therapeutics Inc 주식(MPLT)의 최신 뉴스
Maplight Therapeutics (NASDAQ: MPLT) amends Form 144, lists RSU sale plans - Stock Titan
[144] MapLight Therapeutics, Inc. SEC Filing - Stock Titan
Jefferies (NASDAQ: MPLT) files 144/A listing RSU lots and intended resale - Stock Titan
Form 144: Morgan Stanley Smith Barney (MPLT) resale notice for 8,593 shares - Stock Titan
MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying - Yahoo Finance
All News for MPLT : MapLight Therapeutics, Inc. - Zacks Investment Research
MPLT: MapLight Therapeutics, Inc.Comparison to Industry - Zacks Investment Research
MPLT : MapLight Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 6.9%Time to Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading 8.2% HigherStill a Buy? - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT) - The Globe and Mail
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says AnalystMapLight Therapeutics (NASD - Benzinga
What date does MapLight Therapeutics, Inc.'s (MPLT) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Earns Buy Rating from Analysts at Needham & Company LLC - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Hits New 52-Week HighShould You Buy? - MarketBeat
MPLT: TD Cowen Initiates Coverage with a "Buy" Rating | MPLT Sto - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Coverage Initiated at TD Cowen - MarketBeat
Buy Rating on MapLight: Differentiated CNS Pipeline and Undervalued Schizophrenia Opportunity with Upside in Alzheimer’s and Neuropsychiatric Indications - TipRanks
MapLight2026 Funding Rounds & List of Investors - Tracxn
Maplight Therapeutics (NASDAQ:MPLT) Reaches New 52-Week HighHere's Why - MarketBeat
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
Maplight Therapeutics (NASDAQ:MPLT) Issues Quarterly Earnings Results, Misses Estimates By $1.42 EPS - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
MapLight Therapeutics Announces 2025 Financial Results, Advances Clinical Pipeline for Schizophrenia, Autism, and Alzheimer’s Trials - Minichart
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 5.6%What's Next? - MarketBeat
MapLight Therapeutics 2023 Annual Report: Innovative CNS Drug Discovery, Pipeline, and Risk Factors Overview - Minichart
MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position - TipRanks
Stifel reiterates Buy rating on MapLight Therapeutics stock By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on MapLight Therapeutics stock - Investing.com
MapLight Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MapLight Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
MapLight Therapeutics 10-K: Revenue $0, Net loss $161.2M - TradingView
[10-K] MapLight Therapeutics, Inc. Files Annual Report - Stock Titan
Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share - MarketScreener
MapLight Therapeutics (NASDAQ: MPLT) widens 2025 loss but funds runway through 2027 - Stock Titan
Two Phase 2 readouts ahead as MapLight says cash lasts through 2027 - Stock Titan
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - MarketScreener
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - MarketBeat
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - TipRanks
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - finviz.com
MPLT Earnings History & Surprises | EPS & Revenue Results | MAPLIGHT THERAPEUTICS INC (NASDAQ:MPLT) - ChartMill
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
2.69%
0.25%
자본화:
|
볼륨(24시간):